• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

持续性非卧床腹膜透析治疗开始时血清白蛋白水平对患者生存率的影响。

The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival.

作者信息

Struijk D G, Krediet R T, Koomen G C, Boeschoten E W, Arisz L

机构信息

Department of Medicine, Academic Medical Center, Amsterdam, The Netherlands.

出版信息

Perit Dial Int. 1994;14(2):121-6.

PMID:8043663
Abstract

OBJECTIVE

To analyze the effect of serum albumin using immunoturbidimetry, demographic, biochemical, and kinetic factors on survival of continuous ambulatory peritoneal dialysis (CAPD) patients.

DESIGN

A review of prospectively collected data in a 2-year follow-up study of peritoneal transport kinetics.

SETTING

University medical center.

PARTICIPANTS

Sixty-one patients, evaluated within 3 months after the start of CAPD.

MAIN OUTCOME MEASURES

Covariables used in the survival analysis were plasma urea, and creatinine, albumin, hemoglobin, mass transfer area coefficient of creatinine, peritoneal albumin clearance, 4-hour peritoneal albumin loss, net ultrafiltration, age, blood pressure, body mass index, difference between actual and ideal bodyweight, and presence or absence of systemic disease.

RESULTS

Overall survival was 64% at 2 years. Median serum albumin was 30.9 g/L, range 18.1-43.9 g/L. Patients with a serum albumin below the median had a lower survival rate than those higher than the median (2-year survival 49% vs 79%, p = 0.01). Using the Cox model, survival was related to systemic disease (p = 0.004), age (p = 0.02), hemoglobin (p = 0.03), and serum albumin (p = 0.1).

CONCLUSIONS

The results confirm the strength of serum albumin as predictor of survival. However, in this study serum albumin merely reflected the presence of a systemic disease, which was the most important risk factor for patient survival.

摘要

目的

分析采用免疫比浊法测定的血清白蛋白、人口统计学、生化及动力学因素对持续性非卧床腹膜透析(CAPD)患者生存的影响。

设计

对一项为期2年的腹膜转运动力学随访研究中前瞻性收集的数据进行回顾。

地点

大学医学中心。

参与者

61例患者,在开始CAPD后3个月内接受评估。

主要观察指标

生存分析中使用的协变量包括血浆尿素、肌酐、白蛋白、血红蛋白、肌酐的物质转运面积系数、腹膜白蛋白清除率、4小时腹膜白蛋白丢失量、净超滤量、年龄、血压、体重指数、实际体重与理想体重之差以及是否存在全身性疾病。

结果

2年时总生存率为64%。血清白蛋白中位数为30.9 g/L,范围为18.1 - 43.9 g/L。血清白蛋白低于中位数的患者生存率低于高于中位数的患者(2年生存率49%对79%,p = 0.01)。使用Cox模型,生存与全身性疾病(p = 0.004)、年龄(p = 0.02)、血红蛋白(p = 0.03)和血清白蛋白(p = 0.1)有关。

结论

结果证实血清白蛋白作为生存预测指标的有效性。然而,在本研究中血清白蛋白仅反映了全身性疾病的存在,而全身性疾病是患者生存的最重要危险因素。

相似文献

1
The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival.持续性非卧床腹膜透析治疗开始时血清白蛋白水平对患者生存率的影响。
Perit Dial Int. 1994;14(2):121-6.
2
Peritoneal transport characteristics, comorbid diseases and survival in CAPD patients.持续性非卧床腹膜透析患者的腹膜转运特性、合并症与生存率
Perit Dial Int. 2000 Sep-Oct;20(5):541-7.
3
Patient and technique survival in continuous ambulatory peritoneal dialysis in a single center of the west of Mexico.墨西哥西部单一中心持续性非卧床腹膜透析患者及技术生存率
Rev Invest Clin. 2007 May-Jun;59(3):184-91.
4
Predictors of patient survival in continuous ambulatory peritoneal dialysis: 10-year experience in 2 major centers in Tehran.持续性非卧床腹膜透析患者生存的预测因素:德黑兰两大中心的10年经验
Iran J Kidney Dis. 2010 Jan;4(1):44-9.
5
Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. The Canada-USA (CANUSA) Peritoneal Dialysis Study Group.腹膜转运增加与持续性腹膜透析患者的患者生存率和技术生存率降低相关。加拿大 - 美国(CANUSA)腹膜透析研究小组。
J Am Soc Nephrol. 1998 Jul;9(7):1285-92. doi: 10.1681/ASN.V971285.
6
Markers for survival in dialysis: a seven-year prospective study.透析生存标志物:一项为期七年的前瞻性研究。
Am J Kidney Dis. 1995 Jul;26(1):209-19. doi: 10.1016/0272-6386(95)90176-0.
7
Serum C-reactive protein: a predictor of mortality in continuous ambulatory peritoneal dialysis patients.
Perit Dial Int. 1998 Jul-Aug;18(4):387-94.
8
Relationship between adequacy of dialysis and nutritional status, and their impact on patient survival on CAPD in Hong Kong.香港持续性不卧床腹膜透析患者的透析充分性与营养状况的关系及其对患者生存的影响。
Perit Dial Int. 2001 Sep-Oct;21(5):441-7.
9
Impact of dialysis duration and glucose absorption on nutritional indices in stable continuous ambulatory peritoneal dialysis patients.透析时长及葡萄糖吸收对稳定的持续性非卧床腹膜透析患者营养指标的影响
J Ren Nutr. 2008 Nov;18(6):503-8. doi: 10.1053/j.jrn.2008.06.002.
10
Does serum albumin at start of continuous ambulatory peritoneal dialysis (CAPD) or its drop during CAPD determine patient outcome?持续性非卧床腹膜透析(CAPD)开始时的血清白蛋白水平或其在CAPD期间的下降是否能决定患者的预后?
Adv Perit Dial. 2000;16:119-22.

引用本文的文献

1
Serum albumin at 1 year after peritoneal dialysis predicts long-term outcomes on continuous ambulatory peritoneal dialysis.腹膜透析 1 年后血清白蛋白预测持续性不卧床腹膜透析的长期结局。
Ren Fail. 2022 Dec;44(1):252-257. doi: 10.1080/0886022X.2022.2033264.
2
Exploring Metabolic Signature of Protein Energy Wasting in Hemodialysis Patients.探索血液透析患者蛋白质能量消耗的代谢特征。
Metabolites. 2020 Jul 16;10(7):291. doi: 10.3390/metabo10070291.
3
Time-averaged serum potassium levels and its fluctuation associate with 5-year survival of peritoneal dialysis patients: two-center based study.
腹膜透析患者的时间平均血清钾水平及其波动与5年生存率相关:一项基于两个中心的研究。
Sci Rep. 2015 Oct 28;5:15743. doi: 10.1038/srep15743.
4
Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis.托伐普坦可增加接受腹膜透析的少尿患者的尿量和超滤量。
Clin Exp Nephrol. 2014 Aug;18(4):655-61. doi: 10.1007/s10157-013-0883-8. Epub 2013 Oct 11.
5
The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients.血管紧张素转换酶抑制剂对腹膜透析患者腹膜蛋白丢失和溶质转运的影响。
Clinics (Sao Paulo). 2012 Aug;67(8):877-83. doi: 10.6061/clinics/2012(08)04.
6
Peritoneal albumin and protein losses do not predict outcome in peritoneal dialysis patients.腹膜透析患者的腹膜白蛋白和蛋白丢失并不预示结局。
Clin J Am Soc Nephrol. 2011 Mar;6(3):561-6. doi: 10.2215/CJN.05540610. Epub 2010 Nov 11.